{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:32:18Z","timestamp":1775561538693,"version":"3.50.1"},"reference-count":28,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"published-print":{"date-parts":[[2020,8,26]]},"abstract":"<jats:p>This study aimed to examine serum tenascin C (TNC) in different subsets of axial spondyloarthritis (axSpA) patients. Sixty-one patients fulfilling the Assessment of SpondyloArthritis international Society classification criteria for axSpA and 20 healthy subjects (HS) were included in study. Based on imaging, patients were classified as non-radiographic (n=16) and radiographic (n=45) axSpA. TNC serum levels were determined by ELISA. Disease-related factors including the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and C-reactive protein (CRP) levels were determined. TNC levels were elevated in axSpA patients [535.3 (457.7\u2013677.2) ng\/ml] compared to HS [432.1 (329.1\u2013565.9) ng\/ml, p=0.007]. Dividing axSpA into radiographic and non-radiographic subsets, the difference in TNC was observed between the radiographic subset and HS [535.3 (434.5\u2013677.2) vs. 432.1 (329.1\u2013565.9) ng\/ml, p=0.022]. TNC levels did not correlate with disease activity measures (serum CRP or BASDAI). Nevertheless, the weak correlation of TNC levels with different disease stages (r=0.25, p=0.025) was found, with the highest levels in patients with syndesmophytes. TNC levels are elevated across various subsets of axSpA, and although not related to systemic disease activity, TNC levels might reflect chronic structural spinal changes in axSpA patients. However, its specific role in bone metabolism should be elucidated in further studies.<\/jats:p>","DOI":"10.33549\/physiolres.934414","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T12:47:00Z","timestamp":1598532420000},"page":"653-660","source":"Crossref","is-referenced-by-count":7,"title":["Elevated tenascin-C serum levels in patients with axial spondyloarthritis"],"prefix":"10.33549","author":[{"given":"K","family":"Bubov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Prajzlerov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Hulejov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Gregov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Mint\u00e1lov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Hu\u0161\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0160","family":"Forejtov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Filkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Tom\u010d\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Vencovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Pavelka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"\u0160enolt","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology, Prague, Czech Republic. senolt@revma.cz"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"19169","published-online":{"date-parts":[[2020,6,25]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"AMONKAR SD, BERTENSHAW GP, CHEN TH, BERGSTROM KJ, ZHAO J, SESHAIAH P, YIP P, MANSFIELD BC: Development and preliminary evaluation of a multivariate index assay for ovarian cancer. PLoS One 4: e4599, 2009. https:\/\/doi.org\/10.1371\/journal.pone.0004599","DOI":"10.1371\/journal.pone.0004599"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"BUBOVA K, FOREJTOVA S, ZEGZULKOVA K, GREGOVA M, HUSAKOVA M, FILKOVA M, HORINKOVA J, GATTEROVA J, TOMCIK M, SZCZUKOVA L, PAVELKA K, SENOLT L: Cross-sectional study of patients with axial spondyloarthritis fulfilling imaging arm of ASAS classification criteria: baseline clinical characteristics and subset differences in a single-centre cohort. BMJ Open 9: e024713, 2019. https:\/\/doi.org\/10.1136\/bmjopen-2018-024713","DOI":"10.1136\/bmjopen-2018-024713"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"DEODHAR SD: C-reactive protein: the best laboratory indicator available for monitoring disease activity. Cleve Clin J Med 56: 126-130, 1989. https:\/\/doi.org\/10.3949\/ccjm.56.2.126","DOI":"10.3949\/ccjm.56.2.126"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"DINCER U, CAKAR E, KIRALP MZ, DURSUN H: Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. Clin Rheumatol 27: 457-462, 2008. https:\/\/doi.org\/10.1007\/s10067-007-0727-6","DOI":"10.1007\/s10067-007-0727-6"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"FOREJTOVA S, MANN H, STOLFA J, VEDRAL K, FENCLOVA I, NEMETHOVA D, PAVELKA K: Factors influencing health status and disability of patients with ankylosing spondylitis in the Czech Republic. Clin Rheumatol 27: 1005-1013, 2008. https:\/\/doi.org\/10.1007\/s10067-008-0845-9","DOI":"10.1007\/s10067-008-0845-9"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"GUPTA L, BHATTACHARYA S, AGGARWAL: Tenascin-C, a biomarker of disease activity in early ankylosing spondylitis. Clin Rheumatol 37: 1401-1405, 2018. https:\/\/doi.org\/10.1007\/s10067-017-3938-5","DOI":"10.1007\/s10067-017-3938-5"},{"key":"ref6","unstructured":"HASEGAWA M, HIRATA H, SUDO A, KATO K, KAWASE D, KINOSHITA N, YOSHIDA T, UCHIDA A: Tenascin-C concentration in synovial fluid correlates with radiographic progression of knee osteoarthritis. J Rheumatol 31: 2021-2016, 2004."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"HASEGAWA M, NAKOSHI Y, MURAKI M, SUDO A, KINOSHITA N, YOSHIDA T, UCHIDA A: Expression of large tenascin-C splice variants in synovial fluid of patients with rheumatoid arthritis. J Orthop Res 25: 563-568, 2007. https:\/\/doi.org\/10.1002\/jor.20366","DOI":"10.1002\/jor.20366"},{"key":"ref8","unstructured":"JONES SD, CALIN A, STEINER A: An update on the Bath Ankylosing Spondylitis Disease Activity and Functional Indices (BASDAI, BASFI): excellent Cronbach's alpha scores. J Rheumatol 23: 407, 1996."},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"MAKSYMOWYCH WP: An update on biomarker discovery and use in axial spondyloarthritis. Expert Rev Mol Diagn 17: 965-974, 2017. https:\/\/doi.org\/10.1080\/14737159.2017.1381562","DOI":"10.1080\/14737159.2017.1381562"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"MIDWOOD K, SACRE S, PICCININI AM, INGLIS J, TREBAUL A, CHAN E, DREXLER S, SOFAT N, KASHIWAGI M, OREND G, BRENNAN F, FOXWELL B: Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 15: 774-780, 2009. https:\/\/doi.org\/10.1038\/nm.1987","DOI":"10.1038\/nm.1987"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"MIDWOOD KS, CHIQUET M, TUCKER RP, OREND G: Tenascin-C at a glance. J Cell Sci 129: 4321-4327, 2016. https:\/\/doi.org\/10.1242\/jcs.190546","DOI":"10.1242\/jcs.190546"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"MIDWOOD KS, OREND G: The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal 3: 287-310, 2009. https:\/\/doi.org\/10.1007\/s12079-009-0075-1","DOI":"10.1007\/s12079-009-0075-1"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"PAGE TH, CHARLES PJ, PICCININI AM, NICOLAIDOU V, TAYLOR PC, MIDWOOD KS: Raised circulating tenascin-C in rheumatoid arthritis. Arthritis Res Ther 14: R260, 2012. https:\/\/doi.org\/10.1186\/ar4105","DOI":"10.1186\/ar4105"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"PODDUBNYY DA, RUDWALEIT M, LISTING J, BRAUN J, SIEPER J: Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis 69: 1338-1341, 2010. https:\/\/doi.org\/10.1136\/ard.2009.120139","DOI":"10.1136\/ard.2009.120139"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"PRAJZLEROVA K, GROBELNA K, PAVELKA K, SENOLT L, FILKOVA M: An update on biomarkers in axial spondyloarthritis. Autoimmun Rev 15: 501-509, 2016. https:\/\/doi.org\/10.1016\/j.autrev.2016.02.002","DOI":"10.1016\/j.autrev.2016.02.002"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"RUDWALEIT M, BRAUN J, SIEPER J, ASSESSMENT OF SPONDYLOARTHRITIS INTERNATIONAL S: [ASAS classification criteria for axial spondyloarthritis]. Z Rheumatol 68: 591-593, 2009. https:\/\/doi.org\/10.1007\/s00393-009-0510-y","DOI":"10.1007\/s00393-009-0510-y"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"RUHMANN M, PICCININI AM, KONG PL, MIDWOOD KS: Endogenous activation of adaptive immunity: tenascin-C drives interleukin-17 synthesis in murine arthritic joint disease. Arthritis Rheum, 64: 2179-2190, 2012. https:\/\/doi.org\/10.1002\/art.34401","DOI":"10.1002\/art.34401"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"SATO A, AONUMA K, IMANAKA-YOSHIDA K, YOSHIDA T, ISOBE M, KAWASE D, KINOSHITA N, YAZAKI Y, HIROE M: Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol 47: 2319-2325, 2006. https:\/\/doi.org\/10.1016\/j.jacc.2006.03.033","DOI":"10.1016\/j.jacc.2006.03.033"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"SHAO H, KIRKWOOD JM, WELLS A: Tenascin-C Signaling in melanoma. Cell Adh Migr 9: 125-130, 2016. https:\/\/doi.org\/10.4161\/19336918.2014.972781","DOI":"10.4161\/19336918.2014.972781"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"SHUKLA A, GAUR P, AGGARWAL A: Tenascin-C levels, a toll-like receptor 4 ligand, in enthesitis-related arthritis category of juvenile idiopathic arthritis: A cross-sectional and longitudinal study. J Rheumatol 42: 891-896, 2015. https:\/\/doi.org\/10.3899\/jrheum.141365","DOI":"10.3899\/jrheum.141365"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"SIEPER J, PODDUBNYY D: Axial spondyloarthritis. Lancet 390: 73-84, 2017. https:\/\/doi.org\/10.1016\/S0140-6736(16)31591-4","DOI":"10.1016\/s0140-6736(16)31591-4"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"SORENSEN J, HETLAND ML: Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 74: e12, 2015. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204867","DOI":"10.1136\/annrheumdis-2013-204867"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"SPOORENBERG A, VAN DER HEIJDE D, DE KLERK E, DOUGADOS M, DE VLAM K, MIELANTS H, VAN DER TEMPEL H, VAN DER LINDEN S: Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26: 980-984, 1999.","DOI":"10.1093\/rheumatology\/keh595"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"TANAKA H, EL-KAREF A, KAITO M, KINOSHITA N, FUJITA N, HORIIKE S, WATANABE S, YOSHIDA T, ADACHI Y: Circulating level of large splice variants of tenascin-C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C. Liver Int, 26: 311-318, 2006. https:\/\/doi.org\/10.1111\/j.1478-3231.2005.01229.x","DOI":"10.1111\/j.1478-3231.2005.01229.x"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"UDALOVA IA, RUHMANN M, THOMSON SJ, MIDWOOD KS: Expression and immune function of tenascin-C. Crit Rev Immunol 31: 115-45, 2011. https:\/\/doi.org\/10.1615\/CritRevImmunol.v31.i2.30","DOI":"10.1615\/critrevimmunol.v31.i2.30"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"VAN DER LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27: 361-368, 1984. https:\/\/doi.org\/10.1002\/art.1780270401","DOI":"10.1002\/art.1780270401"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Z\u00c1VADA J, UHER M, SVOBODOV\u00c1 R, OLEJ\u00c1ROV\u00c1 M, HU\u0160\u00c1KOV\u00c1 M, CIFERSK\u00c1 H, HULEJOV\u00c1 H, TOM\u010c\u00cdK M, \u0160ENOLT L, VENCOVSK\u00dd J: Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate. Arthritis Res Ther 17: 341, 2015. https:\/\/doi.org\/10.1186\/s13075-015-0862-4","DOI":"10.1186\/s13075-015-0862-4"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T12:47:06Z","timestamp":1598532426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biomed.cas.cz\/physiolres\/pdf\/2020\/69_653.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":28,"URL":"https:\/\/doi.org\/10.33549\/physiolres.934414","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,25]]}}}